ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments Post author:admERY Post published:October 23, 2014 Post category:Newsroom ERYTECH announces today the successful completion of a capital increase for a total amount of €30 million. You Might Also Like ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia June 9, 2020 ERYTECH Pharma Voting Results by Resolution from Annual General Meeting Held on June 21, 2019 July 4, 2019 ERYTECH Appoints Allene M. Diaz to its Board of Directors September 5, 2016
ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia June 9, 2020
ERYTECH Pharma Voting Results by Resolution from Annual General Meeting Held on June 21, 2019 July 4, 2019
